Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study

Clinical Lymphoma, Myeloma & Leukemia
Adi Shacham-AbulafiaUri Rozovski

Abstract

The strict recruitment criteria of patients for clinical trials often lead to reduced generalizability of the findings. We studied how ponatinib is used outside clinical trials in patients with chronic myeloid leukemia (CML). The present retrospective study included all patients with a diagnosis of CML who had received ponatinib in 7 medical centers in Israel. From 2011 to 2016, we identified 37 patients with CML who had received ponatinib, 21 in the chronic phase and 16 in the advanced phase. Only 9 patients (26%) harbored the T315I (threonine to isoleucine mutation at position 315) mutation. All patients had received ≥ 1 previous tyrosine kinase inhibitor. The median age in our cohort was 43 years (range, 9-82 years), significantly younger than expected for patients with relapsed or refractory CML and 20 years younger than the median age of patients who participated in the PACE (ponatinib Philadelphia-positive acute lymphoblastic leukemia and CML evaluation) trial. During a median follow-up of 14 months (range, 1-51 months), the overall response rate was 85%. Of 34 patients, 16 (47%) experienced at least a major molecular response. Of the 37 total patients, another 16 patients (43%) discontinued treatment because of disease p...Continue Reading

Citations

Mar 8, 2020·European Journal of Haematology·Luigia LucianoGiorgina Specchia
Jul 19, 2020·Journal of Clinical Medicine·Valentín García-Gutiérrez, Juan Carlos Carlos Hernández-Boluda
Apr 5, 2019·Cell Proliferation·Xiaodiao KangZhi-Wei Wang
Sep 12, 2020·International Journal of Molecular Sciences·Peng Zeng, Alvin Schmaier
Mar 12, 2019·Therapeutic Advances in Hematology·Matteo MolicaMassimo Breccia
Jun 6, 2019·Acta Haematologica·Anat Gafter-GviliDaniel Shepshelovich

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.